A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N′-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives, and methods for prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (II):

##STR00001##

The present methods include administering to a subject an effective amount of one or more compounds of Formula (II). In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Provided is a novel method for treating cancer with a high antitumor effect. The present invention provides an antitumor agent comprising an azabicyclo compound of the following Formula (I) or a salt thereof and a poly(adenosine 5′-diphosphate-ribose) polymerase inhibitor which are administered in combination.

##STR00001##

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.

The current invention concerns an innovative treatment for mitochondrial disorders and diseases or conditions associated with mitochondrial dysfunction. In particular, effective and safe dosages of compounds suitable for the treatment of mitochondrial disorders have been established, providing for new treatment regimens and patient populations.

Disclosed are means, methods, and protocols useful for treatment of cancer through the previously unknown immune stimulatory effects of mTOR inhibitors and derivatives/analogues thereof. In one embodiment the invention provides the use of mTOR inhibitors to overcome cancer mediated immune exhaustion/anergy. While in conventional situations it is widely known that mTOR inhibitors possesses immune suppressive functions, hence their use in prevention of allograft rejection, our findings suggest that these inhibitors may overcome cancer induced immune suppression and/or exhaustion of immune cell proliferative activities. In some embodiments mTOR inhibitors are utilized together with checkpoint inhibitors. In other embodiments, mTOR inhibitors are administered after lymphodepletion to augment effects of homeostatically expanded lymphocytes.

Disclosed are means, methods, and protocols useful for treatment of cancer through the previously unknown immune stimulatory effects of mTOR inhibitors and derivatives/analogues thereof. In one embodiment the invention provides the use of mTOR inhibitors to overcome cancer mediated immune exhaustion/anergy. While in conventional situations it is widely known that mTOR inhibitors possesses immune suppressive functions, hence their use in prevention of allograft rejection, our findings suggest that these inhibitors may overcome cancer induced immune suppression and/or exhaustion of immune cell proliferative activities. In some embodiments mTOR inhibitors are utilized together with checkpoint inhibitors. In other embodiments, mTOR inhibitors are administered after lymphodepletion to augment effects of homeostatically expanded lymphocytes.